We're here to make a difference!

A Potential New Era in the Treatment of Chronic Kidney Disease

A Potential New Era in the Treatment of Chronic Kidney Disease

LEARN MORE ABOUT
THE CLINICAL TRIAL

A Decision That Impacts You And Your Family

A Decision That Impacts You And Your Family

Chronic kidney disease (CKD) affects approximately 14% of U.S. adults, equating to about 35.5 million people.

African Americans are more than 3 times as likely to have kidney failure compared to White Americans

Asian Americans are 2X’s more likely to develop kidney failure compared to White Americans

Latinos are 1.3X’s more likely to receive a diagnosis of kidney failure compared to the general population.

Chronic kidney disease (CKD) affects approximately 14% of U.S. adults, equating to about 35.5 million people.

African Americans are more than 3 times as likely to have kidney failure compared to White Americans

Asian Americans are 2X’s more likely to develop kidney failure compared to White Americans

Latinos are 1.3X’s more likely to receive a diagnosis of kidney failure compared to the general population.

The PROACT 1 clinical trial is a Phase 3 study to test a new potential intervention called rilparencel.

The PROACT 1 clinical trial is a Phase 3 study to test a
new potential intervention called rilparencel.